866-997-4948(US-Canada Toll Free)

Reolysin (Head and Neck Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Head and Neck Cancer

No. of Pages : 34 Pages

 

GlobalDatas pharmaceuticals report, Reolysin(Head and Neck Cancer )-Analysis and Forecasts to 2020 provides Reolysin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Head and Neck Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Reolysin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Reolysin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Reolysin in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

 

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 7
2.4 GlobalData Pipeline Report Guidance 8


3 Head and Neck Cancer Disease: Market Characterization 9
3.1 Head and Neck Cancer Disease Market 9
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 9
3.3 Drivers for the Head and Neck Cancer Disease Market 10
3.3.1 High Incidence 10
3.3.2 Low Initial Diagnosis Rate 11
3.3.3 Emergence of Targeted Therapies and Vaccines 11


4 Tumor NodeMetastases (TNM) Classification of Head and Neck Cancer 12


5 Reolysin 20
5.1 Introduction 20
5.2 Mechanism of Action 20
5.3 Clinical Studies 20
5.4 Sales Drivers 21
5.4.1 Improved Response Rate with Less Toxicity 21
5.4.2 Niche Market 21
5.4.3 Unmet Need 21
5.5 Drug Evaluation 21
Drug Risk Benefit Score 21
5.5.1 Efficacy 22
5.5.2 Safety 22
5.5.3 Compliance 22
5.5.4 Dosing Convenience 22
5.6 Intensity of Competition 22
5.7 Sales forecast 22
5.7.1 Target patient Pool of Reolysin 22
5.7.2 Dosing 24
5.7.3 Market Penetration 24
5.7.4 Annual Cost of Therapy 24
5.7.5 Sales Projections of Reolysin 24


6 Head and Neck Cancer Market: Appendix 30
6.1 Market Definitions 30
6.2 Abbreviations 30
6.3 Research Methodology 30
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 33
6.3.7 Annual Cost of Therapy 33
6.3.8 Primary Research 33
6.3.9 Expert Panels 33
6.4 Contact Us 34
6.5 Disclaimer 34
6.6 Sources 34

List of Table

 

Table 1: Head and Neck Cancer, Incidences and Mortality, 2008-2030 4

Table 2: Head and Neck Cancer, Global, Market Forecasts($bn), 20092020 9

Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 12

Table 4: TNM Classification of the Nasopharyngeal Cancer 17

Table 5: Drug Risk Benefit Score of Reolysin 21

Table 6: Head and Neck Cancer, Global, Estimated Sales of Reolysin ($m) 2014-2020 25

Table 7: Head and Neck Cancer, The US, Estimated Sales of Reolysin ($m) 2014-2020 26

Table 8: Head and Neck Cancer, The UK, Estimated Sales of Reolysin ($m) 2014-2020 27

Table 9: Head and Neck Cancer, France, Estimated Sales of Reolysin ($m) 2014-2020 27

Table 10: Head and Neck Cancer, Germany, Estimated Sales of Reolysin ($m) 2014-2020 28

Table 11: Head and Neck Cancer, Italy, Estimated Sales of Reolysin ($m) 2014-2020 28

Table 12: Head and Neck Cancer, Spain, Estimated Sales of Reolysin ($m) 2014-2020 29

List of Chart

 

Figure 1: Percentage Distribution of Top 20 Cancers, Based on Incidence Global, 2008 5

Figure 2: Percentage Distribution of Top 20 Cancers, Based on Mortality Global, 2008 5

Figure 3: Difference Between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 6

Figure 4: Percentage Distribution of Various Cancer Types in Head and Neck Considering US, EU-5 and Japan Incidence, 2008 6

Figure 5: Percentage Distribution of Various Cancer Types in Head and Neck Considering Global Incidence, 2008 7

Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 7

Figure 7: Head and Neck Cancer, Global, Market Forecasts ($bn), 20092020 9

Figure 8: Oncology Incidence (in billion), Global, 2008-2030 10

Figure 9: Head and Neck Cancer Incidence (in billion), Global, 2008-2030 10

Figure 10: Broad Classification of Head and Neck Cancer 12

Figure 11: Detailed TNM Classification of Oral Cavity Cancer 13

Figure 12: Detailed TNM Classification of Laryngeal Cancer 14

Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 15

Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 16

Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 18

Figure 16: Classification of Head and Neck Cancer 18

Figure 17: Drug Model Diagram of Reolysin in the US and EU 24

Figure 18: Head and Neck Cancer, Global, Estimated Sales of Reolysin ($m) 2014-2020 25

Figure 19: Head and Neck Cancer, the US and EU, Reolysin Sales Distribution, 2020 25

Figure 20: Head and Neck Cancer, the US, Estimated Sales of Reolysin ($m) 2014-2020 26

Figure 21: Head and Neck Cancer, The UK, Estimated Sales of Reolysin ($m) 2014-2020 26

Figure 22: Head and Neck Cancer, France, Estimated Sales of Reolysin ($m) 2014-2020 27

Figure 23: Head and Neck Cancer, Germany, Estimated Sales of Reolysin ($m) 2014-2020 27

Figure 24: Head and Neck Cancer, Italy, Estimated Sales of Reolysin ($m) 2014-2020 28

Figure 25: Head and Neck Cancer, Spain, Estimated Sales of Reolysin ($m) 2014-2020 28

Figure 26: GlobalData Methodology 30

Figure 27: Drug Model Diagram 32

Figure 28: Patients Approved for the Drug 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *